COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.11B
Enterprise ValueCHF1.25B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Jul 23, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF145.00Price Target Upside48.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity provide durable financial flexibility. This reduces refinancing and interest-rate risk, supports funding of R&D or clinical programs during downturns, and preserves optionality for partnerships or opportunistic M&A without immediate liquidity strain.
High-margin Operating PotentialThe company has demonstrated the ability to deliver very high margins when commercial execution aligns, indicating strong product economics and pricing power in core gastroenterology niches. That structural profitability potential supports scalable returns when revenues normalize.
Partner/licensing-driven Business ModelA diversified, partner-centric model reduces the cash burden of global commercialization and enables capital-light expansion into new territories. Milestones and royalties create non-linear upside while partners can carry late-stage development or distribution costs, lowering execution risk.
Bears Say
Highly Volatile ResultsLarge swings in revenue and profitability indicate reliance on episodic events (e.g., one-off sales or milestone timing) rather than steady recurring demand. Persistent volatility undermines planning, makes investment decisions harder, and raises the risk that strong-margin years are non-repeatable.
Negative Operating And Free Cash FlowA swing to cash burn reduces internal funding for R&D and commercialization and increases reliance on the balance sheet or external financing. Even with a strong equity base, sustained negative cash flow would erode flexibility and could force dilutive raises or slowed program investment.
Revenue Sustainability RiskA precipitous revenue decline signals fragile demand or dependence on nonrecurring income streams. Without a broader, more resilient product mix or recurring revenues, the company faces ongoing top-line risk that impairs long-term planning and the ability to support consistent profitability.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.11B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2026 which is in 26 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.184 by -CHF0.276.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.936 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.184. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF145.00
▲(48.26% Upside)
Technical Analysis
Options Prices
Currently, No data available
---